Table VI.
RANKL/OPG ratio. RANKL and OPG RQ ratio.
| SAMPLES | RQ values
|
RANKL/OPG RATIO | |
|---|---|---|---|
| RANKL | OPG | ||
| hMSC-48 h | 1.000 | 1.000 | 1.000 |
| hMSC+OGM-48 h | 0.707 | 0.789 | 0.897 |
| ARNEIS LC-48 h | 0.300 | 2.533 | 0.118 |
| CROATINA LC-48 h | 0.987 | 1.954 | 0.505 |
| ARNEIS HC-48 h | 0.653 | 1.288 | 0.507 |
| CROATINA HC-48 h | 0.852 | 1.970 | 0.433 |
| hMSC-7 days | 0.389 | 2.153 | 0.181 |
| hMSC+OGM-7 days | 1.264 | 1.302 | 0.971 |
| ARNEIS LC-7 days | 0.205 | 2.430 | 0.084 |
| CROATINA LC-7 days | 0.379 | 3.033 | 0.125 |
| ARNEIS HC-7 days | 0.215 | 1.646 | 0.131 |
| CROATINA HC-7 days | 0.432 | 3.894 | 0.111 |
RQ, relative quantity; RANKL, receptor activator of nuclear factor κ-B ligand; OPG, osteoprotegerin; HC, high concentration; LC, low concentration; hMSCs, human mesenchymal cells.